Cost-effectiveness could affect the uptake of Spravato for the treatment of MDD

Spravato is estimated to cost $198,000 per quality-adjusted life year (QALY) gained, exceeding the commonly cited cost-effectiveness thresholds of between $50,000–150,000 per QALY.



  • Spravato cost